Data / Form D filings / Allosteros Therapeutics Inc.
Allosteros Therapeutics Inc.: Form D filings
Allosteros Therapeutics Inc., a biotechnology company in Palo Alto, United States, filed 2 Form D notices with the SEC between 2010 and 2012. The latest, on August 24, 2012, reports $286,000 sold of a $286,000 offering to 1 investor.
Find out what Allosteros Therapeutics Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 560 PENA COURT, Palo Alto, United States, 94306
- Phone
- (650) 644-7559
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2009
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1503753
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 24, 2012 | New notice | $286,000 | $286,000 | $0 | 1 | Aug 1, 2012 | sec.gov |
| Oct 18, 2010 | New notice | $1,025,000 | $1,025,000 | $0 | 1 | Apr 7, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Howard Schulman | Executive Officer, Director | |
| Mark Anderson | Director |
Every Form D from the week of Aug 20, 2012 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Allosteros Therapeutics Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.